All In Biotech

Drug Trial Radar · NCT07875881

A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer

A Phase 3, Randomized, Double Blind, Placebo Controlled Study of Deutenzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With High-Risk Biochemical Recurrence (BCR) of Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,044 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,044

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2031

Sponsor

Lead sponsor
Hinova Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double- blind, placebo-controlled Phase III trial to evaluate the efficacy and safety of Deutenzalutamide plus ADT versus placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer after definitive therapy.

Conditions

  • High Risk Biochemical Recurrence (BCR)
  • Deutenzalutamide Soft Capsules

Interventions

  • Deutenzalutamide Soft Capsules + ADTDrug

    Deutenzalutamide Soft Capsules 80mg(Two capsules),QD, oral; ADT (Goserelin Acetate Sustained-release Implant) 10.8mg per dose, administered once every 12 weeks

  • Placebo + ADTDrug

    Placebo Two capsules,QD, oral; ADT (Goserelin Acetate Sustained-release Implant) 10.8mg per dose, administered once every 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MFS evaluated by BICRTime frame: Baseline, Week 25, 49 and every 24 weeks thereafter (± 5 days)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.